296 related articles for article (PubMed ID: 35051024)
21. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
22. Switching from onabotulinum toxin A to abobotulinum toxin A for treating detrusor overactivity in spinal cord injured patient, does it really work?
Le Roy C; Lefèvre C; Lepoittevin L; Reiss B; Le Fort M; Rigaud J; Perrouin-Verbe B; Perrouin-Verbe MA
Prog Urol; 2023 Sep; 33(10):503-508. PubMed ID: 37550178
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
[TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
Conte A; Giannantoni A; Proietti S; Giovannozzi S; Fabbrini G; Rossi A; Porena M; Berardelli A
Eur J Neurol; 2012 May; 19(5):725-32. PubMed ID: 22212295
[TBL] [Abstract][Full Text] [Related]
25. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
[TBL] [Abstract][Full Text] [Related]
26. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
Alloussi SH; Lang Ch; Eichel R; Al-Kaabneh A; Seibold J; Schwentner C; Alloussi S
World J Urol; 2012 Jun; 30(3):367-73. PubMed ID: 21842216
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
Pannek J; Göcking K; Bersch U
BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
[TBL] [Abstract][Full Text] [Related]
28. Effect of intravesical botulinum neurotoxin-A injection on detrusor hyperreflexia in spinal cord injured patients.
Ge XT; Li YF; Wang Q; Zhao JN
Drug Res (Stuttg); 2015 Jun; 65(6):327-31. PubMed ID: 25350080
[TBL] [Abstract][Full Text] [Related]
29. How long does the effect of botulinum toxin in neurogenic patients last? An analysis of the subset of "good responders".
Dominique I; Tremblais B; Charvier K; Nogueira MCS; Paparel P; Journel NM; Ruffion A
Low Urin Tract Symptoms; 2020 May; 12(2):155-161. PubMed ID: 31856406
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.
Koh C; Melling CV; Jennings C; Lewis M; Goyal A
J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328
[TBL] [Abstract][Full Text] [Related]
31. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction.
Utomo E; Groen J; Blok BF
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004927. PubMed ID: 24859260
[TBL] [Abstract][Full Text] [Related]
32. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
Sengoku A; Okamura K; Kimoto Y; Ogawa T; Namima T; Yamanishi T; Yokoyama T; Akino H; Maeda Y
Int J Urol; 2015 Mar; 22(3):306-9. PubMed ID: 25403926
[TBL] [Abstract][Full Text] [Related]
33. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of trigonal BTX-A injections for children with neurological detrusor overactivity secondary to spinal cord injury.
Hui C
J Pediatr Surg; 2020 Dec; 55(12):2736-2739. PubMed ID: 32571538
[TBL] [Abstract][Full Text] [Related]
35. The Stockholm Spinal Cord Uro Study: 3. Urodynamic characteristics in a regional prevalence group of persons with spinal cord injury and indications for improved follow-up.
Farrelly E; Lindbo L; Seiger Å
Scand J Urol; 2021 Oct; 55(5):412-418. PubMed ID: 34279177
[TBL] [Abstract][Full Text] [Related]
36. The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin.
Traini C; Vannucchi MG
Toxins (Basel); 2019 Oct; 11(11):. PubMed ID: 31652991
[TBL] [Abstract][Full Text] [Related]
37. Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury.
Lombardi G; Musco S; Bacci G; Celso M; Bellio V; Del Popolo G
Int Braz J Urol; 2017; 43(4):721-729. PubMed ID: 28537692
[TBL] [Abstract][Full Text] [Related]
38. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
Naqvi S; Clothier J; Wright A; Garriboli M
J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
[TBL] [Abstract][Full Text] [Related]
39. Real-Life Treatment Outcome of Botulinum Toxin A Injection on Overactive Bladder and Voiding Dysfunction in Patients with Central Nervous System Lesions.
Jiang YH; Jhang JF; Chen SF; Kuo HC
Toxins (Basel); 2024 Mar; 16(3):. PubMed ID: 38535789
[TBL] [Abstract][Full Text] [Related]
40. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
Ghalayini IF; Al-Ghazo MA; Elnasser ZA
Int Urol Nephrol; 2009 Dec; 41(4):805-13. PubMed ID: 19184509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
